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In this study, we examined the role of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes (CTLs) in
macaques immunized with an attenuated strain of simian immunodeficiency virus (SIVmac239Dnef) in protection against
pathogenic challenge with SIVmac251. Our results indicate that attenuated SIVmac239Dnef can elicit specific CTL precursor
cells (CTLp), but no correlation was observed between breadth or strength of CTLp response to structural proteins SIV-Env,
-Gamg or -Pol (as measured by limiting dilution assay) and protection against infection. In one animal, we longitudinally
followed the SIV-Gag-specific response to an MHC class I Mamu-A*01-restricted epitope p11C, C-M using a tetrameric
MHC/peptide complex reagent. A low frequency of SIV p11C, C-M peptide-specific tetramer-reactive cells was present at the
time of challenge but could be expanded in vitro. Surprisingly, the low level of Mamu-A*01/p11C, C-M-specific CTLs induced
through attenuated SIVmac239Dnef vaccination increased in the absence of detectable SIVmac251 or SIVmac239Dnef
proviral DNA. Overall, our results suggest that protection against infection in this model can be achieved through more than
one mechanism, with SIV-specific CTLs being important in controlling SIVmac239Dnef viral replication postchallenge. © 2000
Academic Press
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eINTRODUCTION
Nonhuman primate models have been extensively
used to assess candidate human immunodeficiency vi-
rus (HIV) vaccines. The best protection against challenge
with virulent virus has been observed after vaccination
with live attenuated strains of simian immunodeficiency
virus (SIV) (Beer et al., 1997; Desrosiers et al., 1998;
Lohman et al., 1994a; Nilsson et al., 1998; Shibata et al.,
1997; Titti et al., 1997). Animals vaccinated with SIV-
mac239 with a deletion in nef (SIVmac239Dnef) are pro-
tected against challenge with pathogenic strains of SIV-
mac239 and SIVmac251. The ability of live attenuated SIV
to induce protection appears to vary with the degree of
attenuation and length of time after vaccination (Connor
et al., 1998; Desrosiers, 1998; Johnson et al., 1997, 1999;
Langlois et al., 1998; Norley et al., 1996; Wyand et al.,
997, 1999). Although the use of live attenuated viruses in
umans remains controversial, particularly over con-
erns about safety of attenuated vaccines (Desrosiers,
998, 1992; Farthing and Sullivan, 1998), an understand-
ng of the immune correlates of protection in this model
ystem would be of great value for vaccine development.1 To whom reprint requests should be addressed. Fax: (212) 725-
126. E-mail: DNixon@ADARC.org.
20Several studies have evaluated the humoral and cel-
ular immune responses in monkeys immunized with live
ttenuated SIV, but the correlates of protection have
emained elusive (Almond et al., 1997; Connor et al.,
998; Dittmer et al., 1995; Gauduin et al., 1998; Gundlach
t al., 1998; Johnson et al., 1997, 1999; Langlois et al.,
1998; Lohman et al., 1994b; Norley et al., 1996; Stebbings
et al., 1998). Initial studies suggested that maturation of
protective responses took a prolonged period of time to
develop, and the length of time required for protection
increased with greater attenuation of the vaccine virus
(Wyand et al., 1997, 1999). We and others have shown
that protection can be induced as early as 10 weeks after
immunization with attenuated SIV, but a greater degree
of protection can be achieved with a longer period before
challenge (15–25 weeks) (Connor et al., 1998; Norley et
al., 1996). We found that protection was achieved in the
absence of detectable antibodies capable of neutralizing
the SIVmac251 challenge virus in vitro (Connor et al.,
1998), suggesting that cellular immune responses may
play a more critical role in mediating protection. Virus-
specific cytotoxic T lymphocytes (CTLs) have been
shown to suppress SIV replication (Schmitz et al., 1999)
and may have a role in protection against HIV-1 infection
in some exposed but uninfected individuals (Fowke et al.,
1996; Rowland-Jones et al., 1998, 1995). In this study, we
0042-6822/00 $35.00
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204 NIXON ET AL.assessed SIV-specific CTL responses in rhesus ma-
caques immunized with SIVmac239Dnef and challenged
with pathogenic SIVmac251 at 10 or 25 weeks after
vaccination (Connor et al., 1998). We used limiting dilu-
tion analysis and soluble tetrameric MHC/peptide com-
plexes to quantify SIV-specific T cells.
RESULTS
Longitudinal SIV-specific CTLp analysis
The immunological studies reported here were per-
formed on monkeys included in the study by Connor et
al. (1998). Figure 1 shows the changes in SIV plasma
viremia over time (Connor et al., 1998). Animals were
infected intravenously with 2 3 104 TCID50
SIVmac239Dnef and challenged with 10 animal infec-
tious doses (AID) of uncloned SIVmac251 (kindly pro-
vided by Dr. R. Desrosiers) via the same route, either 10
FIG. 1. SIV RNA in plasma after immunization with SIVmac239Dnef
and challenge with SIV mac251. Viremia was determined by measuring
total SIV RNA in plasma in a bDNA assay (sensitivity of 104 RNA
opies/ml). Immunization with SIVmac239Dnef was performed on day
. The animals were then challenged with SIVmac251 at either 10
group B, top) or 25 (group D, bottom) weeks. Levels of SIV RNA for the
on-immunized control animal in each challenge group are designated
) (Rh 1492 group B; Rh 1516 group D).(Fig. 1, top) or 25 (Fig. 1, bottom) weeks later. Nonvacci-
nated control animals in both groups (Rh 1492, 10 weeks;Rh 1516, 25 weeks) became infected with SIVmac251 and
died from simian AIDS.
The CTL precursor frequencies to SIV-Env, -Gag, or
-Pol antigens are shown in Table 1. Based on an
earlier report of the induction of vigorous CTL re-
sponses by attenuated SIV (Johnson et al., 1997), we
had expected to find a high frequency of SIV-specific
CTLp at the time of challenge in the SIVmac239Dnef-
immunized macaques. Six of eight monkeys immu-
nized with SIVmac239Dnef had SIV-specific CTLp
above the level of detection after immunization and
before the day of challenge, although the CTLp fre-
quencies varied (Table 1). The 25-week challenge an-
imals had a lower total mean of CTLp frequencies just
before challenge compared with the 10-week group.
However, we saw no significant difference between
the frequency or breadth of SIV-specific CTLp frequen-
cies after immunization with SIVmac239Dnef and pro-
tection against challenge with pathogenic SIV.
Longitudinal analysis of the Mamu-A*01/p11C, C-M
peptide CD81 T cell response in animal Rh 1484
All animals were typed for the MHC class I Mamu-
*01 allele (D. Watkins, Wisconsin Primate Center) and
ne monkey, Rh 1484 was found positive. In this animal,
e followed the SIV Gag-specific CTL response to the
amu-A*01 Gag-derived p11C, C-M epitope longitudi-
ally (Allen et al., 1998; Miller et al., 1991) using a tet-
americ Mamu-A*01/p11C, C-M peptide complex (Altman
t al., 1996; Kuroda et al., 1998). The tetramer was con-
structed as previously described (Hanke et al., 1999) and
was used to stain a known SIV Gag p11C, C-M CTL line
as positive control. The negative control was peripheral
blood mononuclear cells (PBMCs) from an SIV unin-
fected Mamu-A*01-positive animal (Hanke et al., 1999).
To our knowledge, this is the first report of SIV-specific
CD81 T cell responses to attenuated SIV viruses quan-
tified using the tetramer technology.
The initial measurements of Mamu-A*01/p11C, C-M-
specific T cells after SIVmac239Dnef immunization
showed that a low frequency of up to 0.1% of circulating
CD81 PBMCs reacted with the tetramer (Fig. 2). This CTL
esponse is about 10-fold lower than has been reported
fter infection with pathogenic SIV (Kuroda et al., 1998,
999a,b). There was no correlation between the number
f tetramer positive T cells and the reduction in plasma
iremia. Three weeks after challenge, plasma viremia
as transiently detected at a low level and remained
ndetectable for the duration of the study; however, the
requency of SIV Gag p11C, C-M-specific T cells in-
reased steadily (Fig. 2). This animal had .2% CD81 T
cells specific for SIV Gag 830 days postchallenge and no
detectable SIVmac251 or SIVmac239Dnef proviral DNA
(K. Metzner, personal communication).
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d Rh 1490 was unable to control replication of SIVmac239Dnef and died fro
(Connor et al., 1998).
tetramer is shown on the secondary y axis. Days after immunization is
shown on the x axis.
205SIVDNef-INDUCED CTL AND PROTECTION AGAINST CHALLENGEMamu-A*01/p11C, C-M peptide CD81 T cells killed
eptide pulsed targets in a 51Cr release assay
To assess the ability of tetramer-positive cells to
ount effector functions in vitro, PBMCs at 14 and 781
ays after SIVmac239Dnef immunization were expanded
n vitro with the p11C, C-M peptide (1 mg/ml) and inter-
leukin-2 (IL-2) and stained with tetramer after 7 days of in
vitro culture (Fig. 3B). Even though there was less than
0.1% SIV Gag p11C, C-M-specific CD81 T cells in fresh
lood at 14 days postimmunization, p11C, C-M tetramer-
eactive T cells could be expanded (Fig. 3B). Functional
TLs were also expanded at the other time points tested
Fig. 3C).
DISCUSSION
Our results indicate that CTLs are induced in rhesus
acaques after immunization with a live, attenuated SIV
accine; however, we found no correlation between SIV-
pecific CTLp frequencies and protection from patho-
ncies in Rhesus Macaques
Day
SIV CTLpc
env gag pol
49 pre 16 187 ,15
49 pre 28 39 46
49 pre ,15 ,15 ,15
49 pre 46 94 66
49 pre ,15 ,15 ,15
63 pre ,15 ,15 ,15
139 pre 103 67 ,15
195 post 45 219 ND
63 pre 25 23 20
139 pre 17 ,15 ,15
180 post 350 ,15 42
63 pre 340 ,15 36
139 pre ,15 ,15 ,15
195 post 403 ,15 ,15
21 pre ,15 ,15 ,15
63 pre ,15 ,15 ,15
139 pre ,15 ,15 ,15
195 post ,15 ,15 ,15
63 pre ,15 ,15 ,15
139 pre ,15 ,15 ,15
195 post ,15 16 16
nested DNA PCR (Connor et al., 1998). NP, not protected; P, protected;
munization with SIVmac239Dnef using 10 AID SIVmac251 (Connor et
ag, and pol antigens. Recombinant vaccinia viruses were vAbT252
Results are expressed as CTLp/106 PBMCs. Background CTLp was
m simian AIDS. No evidence for infection with SIVmac251 was foundTABLE 1
SIV-Specific CTL Precursor Freque
Macaque Protectiona Challengeb
1482 NP 10
1484 NP 10
1488 P 10
1490 Pd 10
1492 C 10
1506 P 25
1510 NP 25
1512 P 25
1514 P 25
1516 C 25
a Protection was defined as a failure to detect SIVmac251nef sequences by
, control.
b Macaques were challenged intravenously at either 10 or 25 weeks after im
al., 1998). CTLp was measured before (pre) or after (post) challenge.
c SIV CTLp was measured using limiting dilution analysis for SIV env, g
(SIVmac251 gag), vAbT258 (SIVmac251 pol), and vAbT253 (SIVmac251 env).
15/106 PBMCs. ND, not determined.FIG. 2. Longitudinal analysis of SIV Gag p11, C-M-specific tetramer-
positive CTLs in group B animal Rh 1484. This animal was immunized
with SIVmac239Dnef and challenged with SIV mac251 10 weeks later.
Plasma viremia is shown on the y axis (sensitivity of 104 RNA copies/
ml), and percentage of CD81 T cells specific for the SIV Gag p11C, C-Menic SIV challenge. Relatively few studies have quanti-
ied the CTLp frequencies after vaccination of rhesus
a
U
r
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206 NIXON ET AL.macaques, and comparative analyses of the data are
often complicated by differences in vaccine strategies
and technical variations in the limiting dilution assay
(Gallimore et al., 1995; Hulskotte et al., 1995; Johnson et
al., 1997; Kent et al., 1996; Yasutomi, 1995). Of particular
relevance to the current study, Johnson et al. (1997)
reported vigorous CTL responses in rhesus macaques
infected with live, attenuated strains of SIV. Their findings
indicate that CTLs are maintained at relatively high lev-
els throughout the course of infection, suggesting that
CTLs play an important role in protection. It is worth
noting, however, that CTLp frequency analysis was per-
formed for only two animals, each of which was chroni-
cally infected with SIVmac239Dnef for more than 3 years
(Johnson et al., 1997). In contrast, we evaluated CTLp
frequencies in 10 macaques during the first 6 months
after immunization with SIVmac239Dnef, when protective
responses are known to develop (Connor et al., 1998;
Norley et al., 1996). Interestingly, the CTLp frequencies
measured against SIV-specific proteins both in our study
and that of Johnson et al. (1997) were similar in magni-
FIG. 3. Quantification of SIV Gag p11C, C-M-specific CD81 T cell res
esponses is shown in the top right corner of each FACS panel. Fou
mmunization. (A) Direct staining of PBMCs. (B) Expansion of SIV Gag p
SIV Gag p11C, C-M peptide. (C) Effector CTLs lyse autologous target
effector/target (E/T) ratio is shown on the x axis.tude, indicating that CTL responses can be quantified
both early and late in infection by these methods. More-
c
Sover, these results suggest that our inability to detect
CTLp at certain time points cannot be attributed solely to
technical differences in the limiting-dilution assay. One
possible explanation for the low CTLp frequencies ob-
served in some animals on day 139 after immunization is
a decay in SIV-specific effector CTLs as a result of low or
undetectable virus replication, similar to what has been
observed in HIV-1-infected humans placed on highly-
active antiretroviral therapy (Ogg et al., 1999). In the latter
case, HIV-1-specific CTL responses decayed exponen-
tially after initiation of therapy, with a median half-life of
45 days, and continued to decline for as long as viremia
remained undetectable.
Our results using tetrameric MHC/peptide staining of
PBMCs from a Mamu-A*01 positive macaque indicate
that immunization with SIVmac239Dnef elicits an SIV-
specific CD81 T cell response at low frequency that
consistently increases 10–15 weeks after immunization.
The stimuli for these prolonged CD81 T-cell expansions
re unknown but indicate a persistence of viral antigen.
sing real-time PCR and a sensitive detection system
. The percentage of SIV Gag p11C, C-M tetramer-positive CD81 T cell
sentative time points are shown from days 14, 77, 307, and 781 after
-M tetramer-positive CD81 T cells after a 7-day in vitro expansion with
lsed with the p11C, C-M peptide (F) but not control peptide (f). Theponses
r repre
11C, Capable of discriminating between SIVmac239Dnef and
IVmac251, we were unable to detect proviral DNA from
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207SIVDNef-INDUCED CTL AND PROTECTION AGAINST CHALLENGESIVmac251 in PBMCs from this animal for more than 2
years after challenge. Only low levels of SIVmac239Dnef
roviral DNA were detected during this period, indicating
ignificant inhibition of both the vaccine and challenge
iruses (K. Metzner, personal communication). In lymph
odes from this animal, both SIVmac239Dnef and SIV-
ac251 were detected by DNA PCR (Sodora et al., 1999),
uggesting that low levels of virus replication in lymphoid
issues may be sufficient to stimulate cellular immune
esponses.
Because of the small number of animals studied and
he absence of any data after pathogenic SIV challenge,
t is not possible to know whether the CTLp frequencies
eported by Johnson et al. (1997) are associated with
rotection from pathogenic SIV infection. Reports by
ther groups have noted the induction of SIV-specific
TL responses in rhesus macaques immunized with live,
ttenuated SIV (Dittmer et al., 1995; Norley et al., 1996)
ut have failed to find a correlation between the pres-
nce of CTLs and protection from challenge with SIV. An
nverse correlation was found between vaccine-induced
ef-specific CTLp frequencies and virus load after chal-
enge with pathogenic SIVmac251 (32H) (Gallimore et al.,
995), suggesting that both the quantitative and qualita-
ive nature of the CTL response may play a critical role in
reventing or containing SIV replication.
To address this issue, we quantified CTLp frequencies
gainst a range of SIV-specific proteins, including Env,
ag, and Pol. Although CTLs were detected against one
r more of the SIV structural proteins in virtually all
acaques immunized with SIVmac239Dnef, we found no
orrelation between CTLp frequency and outcome after
hallenge with SIVmac251. This does not preclude the
ossibility that CTLs play an important role in mediating
rotection from pathogenic SIV-challenge; however, it
oes suggest that other mechanisms may contribute to
locking or inhibiting replication of the challenge virus.
ndeed, recent work by Gauduin et al. (1998 has shown
hat SIV replication can be inhibited in vitro by soluble
actors secreted by CD81 T lymphocytes from rhesus
acaques immunized with live, attenuated SIV. In other
tudies, partial depletion of CD81 T cells in vivo failed to
abrogate protection mediated by a live attenuated SIV
vaccine (Stebbings et al., 1998). However, interpretation
of this result is complicated by the inability to effect
complete and lasting CD81 T cell depletion in peripheral
blood and lymph nodes.
The low frequency of tetramer-positive CD81 T cells
seen in the first few weeks after immunization with
SIVmac239Dnef contrasts with the early induction of vi-
rus-specific CTLs observed during primary infection with
SIV (Kuroda et al., 1999b; Yasutomi et al., 1993) and HIV-1
(Koup et al., 1994). The temporal discrepancy between
the induction of CTL responses during acute SIV infec-
tion (typically 2–3 weeks) and the longer period required
for protective immunity to develop (10–15 weeks) sug-gests that a distinct mechanism may contribute to con-
taining virus replication in a vaccine setting. It is possible
that the delay in developing protection may reflect a
necessary maturation or broadening of the cellular im-
mune response. Alternatively, recent data have high-
lighted protective mechanisms that do not apparently
involve classic antigen-specific immune responses. For
example, prior immunity to one virus can enhance clear-
ance of a second, unrelated virus (Selin et al., 1998), and
noncytopathic antiviral mechanisms can contribute to
viral clearance during acute hepatitis B infection
(Guidotti et al., 1999).
Taking these concepts into consideration, we suggest
that innate and acquired cellular-based immunities may
cooperate to prevent the establishment of long-term in-
fection in animals immunized with an attenuated virus
and “protected” against subsequent pathogenic infec-
tion. In this case, innate immunity may include such
nonspecific effectors as NK cells or NK1.1T cells, which
may be stimulated in response to vaccination. SIV-spe-
cific cellular immunity, including CTLs, may be consid-
ered as acquired immunity, developing during the course
of infection. A humoral immunity model exists for such
protection in influenza virus infection of mice, where
“natural” immunoglobulins are thought to delay pathoge-
nicity of infecting agents until antigen-induced high-af-
finity immunoglobulins are produced (Baumgarth et al.,
1999).
In macaques immunized with attenuated SIV, the cel-
lular immune milieu is primed. On challenge with patho-
genic SIV, innate mechanisms may initially suppress viral
replication while the antigen-specific immune response
develops. The SIV-specific CTL response, in concert with
nonspecific effector mechanisms, may then become the
primary control for residual virus replication. Alterna-
tively, it is possible that infection with pathogenic SIV
stimulates short-lived highly activated CTL effectors with
low affinity for antigen, as has been seen in lymphocytic
choriomeningitis virus infection (Gallimore et al., 1998).
SIVmac239Dnef immunization might stimulate T cells of
higher affinity, which respond earlier and faster to infec-
tion. After infection with L. monocytogens, there is a
selective expansion of high-affinity T cells, with conse-
quent improvement in the quality of immunity (Busch and
Pamer, 1999).
In summary, we quantified SIV-specific CTL responses
in animals immunized with an attenuated virus and chal-
lenged with pathogenic SIV. The quantity of SIV-specific
CTLs recognizing late structural proteins at time of chal-
lenge did not appear to correlate with protection against
pathogenic SIV infection. However, innate and acquired
cellular immune responses may synergize to prevent the
establishment of infection with the challenge virus and
control the attenuated vaccine virus. Our results suggest
that greater emphasis should be placed on the induction
of cellular immune responses for retroviral vaccination.
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208 NIXON ET AL.MATERIALS AND METHODS
Animals
Female rhesus macaques (Macaca mulatta) were
housed either at the Laboratory for Experimental Medi-
cine and Surgery in Primates (Tuxedo, NY) or at the
Tulane Regional Primate Research Center (Covington,
LA). Animals were maintained in accordance with the
guidelines of the local institutional animal use commit-
tee. Eight animals were infected intravenously with 2 3
104 TCID50 SIVmac239Dnef and challenged with 10 ani-
mal infectious doses (AID) of uncloned SIVmac251 (kindly
provided by Dr. R. Desrosiers) using the same route either
10 weeks (Fig. 1, top) or 25 weeks (Fig. 1, bottom) later.
Nonvaccinated control animals in both groups (Rh 1492, 10
weeks; Rh 1516, 25 weeks) became infected with SIV-
mac251 and died from simian AIDS. Two immunized ma-
caques (Rh 1482, 10 weeks; Rh 1510, 25 weeks) were not
protected from challenge and became infected with SIV-
mac251. The plasma viremia profiles for all macaques are
shown in Fig. 1. Rhesus monkeys were screened for the
presence of the Mamu-A*01 allele by a PCR-based tech-
nique (Dr. D. Watkins, Wisconsin Regional Primate Center)
(Evans et al., 1997).
Cell lines
Autologous B-lymphoblastoid cell lines (BCLs) from
study animals were transformed by incubating PBMCs at
37°C with RPMI 1640 (BioWhittaker, Walkersville, MD)
supplemented with R-15 (15% FCS, 10 mM HEPES, 2 mM
L-glutamine, and 50 IU of penicillin/streptomycin) and
erpesvirus papio from the supernatant of S594 cell line
kindly provided by Dr. D. Watkins, Wisconsin Regional
rimate Center, Madison, WI). PBMCs were isolated
rom heparinized or EDTA blood by centrifugation over a
icoll-sodium diatrizoate gradient (Pharmacia, Uppsala,
weden).
imiting dilution analysis
Limiting dilution analysis was performed as previously
escribed (Kakimoto et al., 1999) In brief, cryopreserved
BMCs were thawed, washed twice in R-15, and resus-
ended at 2 3 106 cells/ml in R-15. PBMCs were incu-
ated with Concanavalin A (Sigma) at 5 mg/ml for 3 days
in RPMI 1640 (BioWhittaker) plus 15% FCS (R-15),
washed, and seeded at 500–32,000 cells/100 ml in 24
eplicates of a 96 U-bottom plate with 100 ml of R-15 plus
100 IU of human recombinant IL-2 in the presence of
2.5 3 104 g-irradiated human PBMCs (Kakimoto et al.,
1999). CTL assays were performed 10–14 days after
stimulation. SIV-specific cytolytic activity was measured
using a standard 51Cr release assay with cold target
inhibition and autologous recombinant vaccinia-infected
BCL as targets (Johnson et al., 1997; Kakimoto et al.,
999). Recombinant vaccinia viruses were rVV-GagvAbT252, encoding the SIVmac251 p55gag and protease
roteins), rVV-Env (vAbT2531 encoding the SIVmac251
nvelope) or control (vaccinia thymidine kinase negative)
Therion Biologics, Cambridge, MA). Wells with specific
ysis equal to or greater than 10% were scored as posi-
ive. The fraction of nonresponding wells was deter-
ined for each dilution, and the CTL precursor cell
requency (CTLp) was calculated according to the max-
mum likelihood method (Kakimoto et al., 1999). Limiting
ilution analysis results are presented as CTLp/106 PB-
MCs with negative controls subtracted from experimen-
tal wells.
Peptide-expanded bulk culture cells were tested in a
standard 51Cr release assay on autologous BCL pulsed
for 1 h with or without peptide p11C, C-M (10 mm) (Hanke
t al., 1999; Miller et al., 1991).
Tetramer staining
The soluble Mamu-A*01 p11 C, C-M tetramer was
made as previously described (Hanke et al., 1999). To
quantify tetramer-reactive cells, cryopreserved PBMCs
were thawed and washed twice in R-15. Phycoerythrin-
conjugated Mamu-A*01 p11C, C-M tetramer was added
for 20 min at 37°C, and the suspension was then incu-
bated with anti-CD8 TriColor (Caltag, clone 3B5) for 30
min at 4°C. Cells were washed twice and fixed with 2%
paraformaldehyde in PBS. PBMCs were analyzed for the
expression of cell surface markers and tetramer-positive
cells using a fluorescent activated cell sorter (FACS)
(Calibur; Becton-Dickinson, San Jose, CA) with CellQuest
Software (Becton Dickinson). The mononuclear cell pop-
ulation was gated on the basis of forward and side
scattering properties and subsequently evaluated for the
fluorochromes conjugated to the tetramer and anti-CD8
antibody. Staining of PBMCs identified a distinct popula-
tion of CD8/tetramer double-positive cells. The tetramer
was used to stain a known SIV Gag p11C, C-M CTL line
as positive control, and the negative control were
PBMCs from an SIV-uninfected Mamu-A*01-positive an-
imal.
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